AMRN – Amarin Corp ADR

AMRN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.16

Margin Of Safety %

-21

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.16

EPS Last/This Y

2.58

EPS This/Next Y

0.39

Price

13.94

Target Price

Analyst Recom

Performance Q

-1.34

Upside

-571.7%

Beta

0.78

Ticker: AMRN

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	AMRN	14.34	0.22	0.00	3902
2026-03-04	AMRN	14.56	0.22	0.00	3890
2026-03-06	AMRN	14.05	0.22	0.08	3910
2026-03-09	AMRN	14.65	0.23	0.00	3869
2026-03-10	AMRN	15.99	0.23	0.06	3830
2026-03-11	AMRN	16.34	0.22	0.00	4049
2026-03-12	AMRN	16.28	0.21	0.05	4164
2026-03-13	AMRN	16.37	0.21	0.05	4164
2026-03-17	AMRN	15.52	0.21	0.00	4193
2026-03-18	AMRN	14.95	0.21	0.00	4190
2026-03-20	AMRN	14.49	0.20	0.28	4419
2026-03-25	AMRN	14.72	0.31	0.13	2166
2026-03-26	AMRN	14.65	0.29	0.23	2382
2026-03-27	AMRN	14.44	0.28	0.63	2540
2026-03-30	AMRN	13.88	0.29	0.11	2555
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	AMRN	13.93	-	-	0.59
2026-03-03	AMRN	14.29	-	-	0.59
2026-03-04	AMRN	14.36	-	-	0.59
2026-03-05	AMRN	14.19	-	-	0.59
2026-03-06	AMRN	14.01	-	-	0.59
2026-03-09	AMRN	14.62	142.5	-	0.78
2026-03-10	AMRN	15.92	142.5	-	0.78
2026-03-11	AMRN	16.29	142.5	-	0.78
2026-03-12	AMRN	16.28	142.5	-	0.78
2026-03-13	AMRN	15.33	142.5	-	0.78
2026-03-17	AMRN	15.46	142.5	-	0.78
2026-03-18	AMRN	14.94	142.5	-	0.78
2026-03-19	AMRN	14.95	142.5	-	0.78
2026-03-20	AMRN	14.48	142.5	-	0.78
2026-03-23	AMRN	14.78	142.5	-	0.78
2026-03-24	AMRN	14.47	142.5	-	0.78
2026-03-25	AMRN	14.62	142.5	-	0.78
2026-03-26	AMRN	14.60	142.5	-	0.78
2026-03-27	AMRN	14.32	142.5	-	0.78
2026-03-30	AMRN	13.94	142.5	-	0.78
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	AMRN	0.00	-0.01	1.98
2026-03-03	AMRN	0.00	-0.01	1.98
2026-03-04	AMRN	0.00	-0.01	1.98
2026-03-05	AMRN	0.00	-0.01	1.98
2026-03-06	AMRN	0.00	-0.01	1.98
2026-03-09	AMRN	0.00	-0.01	1.98
2026-03-10	AMRN	0.00	-0.01	1.98
2026-03-11	AMRN	0.00	-0.01	2.11
2026-03-12	AMRN	0.00	-0.01	2.11
2026-03-13	AMRN	0.00	-0.01	2.11
2026-03-18	AMRN	0.00	0.02	2.11
2026-03-19	AMRN	0.00	0.02	2.11
2026-03-20	AMRN	0.00	0.02	2.11
2026-03-23	AMRN	0.00	0.02	2.11
2026-03-24	AMRN	0.00	0.02	2.11
2026-03-25	AMRN	0.00	0.02	2.16
2026-03-26	AMRN	0.00	0.02	2.16
2026-03-27	AMRN	0.00	0.02	2.16
2026-03-30	AMRN	0.00	0.02	2.16
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

0.17

Avg. EPS Est. Next Quarter

0.17

Insider Transactions

Institutional Transactions

0.02

Beta

0.78

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

11.08

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

89.4

Max Drawdown 5-Year %

-93.8

Target Price

P/E

Forward P/E

253.64

PEG

P/S

1.35

P/B

0.63

P/Free Cash Flow

EPS

-1.88

Average EPS Est. Cur. Y

0.78

EPS Next Y. (Est.)

1.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-18.19

Relative Volume

0.68

Return on Equity vs Sector %

-35.9

Return on Equity vs Industry %

-45.1

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.19

EBIT Estimation

◆ AMRN Healthcare

$13.95

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

14/25

Volume

9/15

Valuation

9/20

TP/AR

0/10

Options

8/10

RSI

39.4

Range 1M

33.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

22/30

Estimates

1/20

Inst/Vol

3/15

Options

8/10

EPS Yr

133.3%

EPS NY

83.3%

52W%

53.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +87.8% upside

Quality

5/30

Valuation

19/30

Growth

19/25

Stability

7/10

LT Trend

0/5

Upside

+87.8%

Quality

MoS

-21%

Amarin Corporation plc

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 80

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN

Latest News

—

Caricamento notizie per AMRN…

stock quote shares AMRN – Amarin Corp ADR Stock Price stock today

news today AMRN – Amarin Corp ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch AMRN – Amarin Corp ADR yahoo finance google finance

stock history AMRN – Amarin Corp ADR invest stock market

stock prices AMRN premarket after hours

ticker AMRN fair value insiders trading

GRFS – Grifols, S.A.

GRFS — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.72

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.37

Price

7.56

Target Price

14.32

Analyst Recom

Performance Q

-16.92

Upside

210.2%

Beta

0.74

Ticker: GRFS

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	GRFS	8.65	0.38	1.62	2078
2026-03-04	GRFS	8.65	0.42	0.36	2316
2026-03-06	GRFS	8.59	0.42	999.99	2323
2026-03-09	GRFS	8.75	0.42	1.20	2323
2026-03-10	GRFS	8.19	0.42	2.43	2328
2026-03-11	GRFS	8.02	0.43	22.00	2352
2026-03-12	GRFS	7.97	0.44	999.99	2380
2026-03-13	GRFS	7.97	0.44	999.99	2380
2026-03-17	GRFS	8.02	0.38	1.00	2328
2026-03-18	GRFS	7.86	0.38	0.02	2332
2026-03-20	GRFS	7.57	0.36	999.99	2381
2026-03-25	GRFS	7.69	0.40	0.13	2108
2026-03-26	GRFS	7.62	0.40	0.50	2124
2026-03-27	GRFS	7.49	0.40	0.06	2130
2026-03-30	GRFS	7.57	0.38	0.25	2238
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	GRFS	9.10	-	-	1.20
2026-03-03	GRFS	8.64	-	-	1.20
2026-03-04	GRFS	8.66	-	-	1.20
2026-03-05	GRFS	8.59	-	-	1.20
2026-03-06	GRFS	8.60	-	-	1.20
2026-03-09	GRFS	8.75	-	-	1.20
2026-03-10	GRFS	8.20	-	-	1.20
2026-03-11	GRFS	8.03	-	-	1.20
2026-03-12	GRFS	7.97	-	-	1.20
2026-03-13	GRFS	7.80	-	-	1.20
2026-03-17	GRFS	8.02	-	-	1.20
2026-03-18	GRFS	7.87	-	-	1.20
2026-03-19	GRFS	7.77	-	-	1.20
2026-03-20	GRFS	7.58	-	-	1.20
2026-03-23	GRFS	7.68	-	-	1.20
2026-03-24	GRFS	7.58	-	-	1.20
2026-03-25	GRFS	7.69	-	-	1.20
2026-03-26	GRFS	7.62	-	-	1.20
2026-03-27	GRFS	7.50	-	-	1.20
2026-03-30	GRFS	7.56	-	-	1.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	GRFS	0	-0.68	2.51
2026-03-03	GRFS	0	-0.68	2.51
2026-03-04	GRFS	0	-0.68	2.51
2026-03-05	GRFS	0	-0.68	0
2026-03-06	GRFS	0	-0.68	2.51
2026-03-09	GRFS	0	-1.15	2.51
2026-03-10	GRFS	0	-1.15	2.51
2026-03-11	GRFS	0	-1.15	2.75
2026-03-12	GRFS	0	-1.15	2.75
2026-03-13	GRFS	0	-1.15	2.75
2026-03-17	GRFS	0	-1.38	2.75
2026-03-18	GRFS	0	-1.38	2.75
2026-03-19	GRFS	0	-1.38	2.75
2026-03-20	GRFS	0	-1.38	2.75
2026-03-23	GRFS	0	-1.64	2.75
2026-03-24	GRFS	0	-1.64	2.75
2026-03-25	GRFS	0	-1.64	2.72
2026-03-26	GRFS	0	-1.64	2.72
2026-03-27	GRFS	0	-1.64	2.72
2026-03-30	GRFS	0	-0.96	2.72
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-0.96

Beta

0.74

Average Sales Estimate Current Quarter

1904

Average Sales Estimate Next Quarter

Fair Value

11.71

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

60.4

Max Drawdown 5-Year %

-70.7

Target Price

14.32

P/E

11.22

Forward P/E

5.74

PEG

0.24

P/S

0.23

P/B

0.83

P/Free Cash Flow

2.2

EPS

0.67

Average EPS Est. Cur. Y

1.2

EPS Next Y. (Est.)

1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.39

Relative Volume

0.75

Return on Equity vs Sector %

-20.2

Return on Equity vs Industry %

-29.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ GRFS Healthcare

$7.56

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

21/25

Volume

9/15

Valuation

18/20

TP/AR

2/10

Options

7/10

RSI

32.9

Range 1M

10.2%

Sup Dist

1.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

21/30

Estimates

6/20

Inst/Vol

1/15

Options

10/10

EPS Yr

19.6%

EPS NY

30.2%

52W%

27.8%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +345.5% upside

Quality

13/30

Valuation

28/30

Growth

14/25

Stability

4/10

LT Trend

4/5

Upside

+345.5%

Quality

MoS

55%

Grifols, S.A.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 25258

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS

Latest News

—

Caricamento notizie per GRFS…

stock quote shares GRFS – Grifols, S.A. Stock Price stock today

news today GRFS – Grifols, S.A. stock forecast ,stock prediction 2023 2024 2025

marketwatch GRFS – Grifols, S.A. yahoo finance google finance

stock history GRFS – Grifols, S.A. invest stock market

stock prices GRFS premarket after hours

ticker GRFS fair value insiders trading

SNY – Sanofi

SNY — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.31

Margin Of Safety %

Put/Call OI Ratio

1.02

EPS Next Q Diff

0.22

EPS Last/This Y

1.22

EPS This/Next Y

0.32

Price

46.71

Target Price

56.4

Analyst Recom

1.71

Performance Q

-3.61

Upside

-33.5%

Beta

0.42

Ticker: SNY

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	SNY	46.5	1.00	0.49	57403
2026-03-04	SNY	46.24	0.99	0.32	58022
2026-03-06	SNY	44.52	0.98	0.30	59022
2026-03-09	SNY	44.38	0.97	1.43	59538
2026-03-10	SNY	44	0.98	1.33	61813
2026-03-11	SNY	43.97	0.97	3.66	61836
2026-03-12	SNY	43.65	0.98	0.29	62160
2026-03-13	SNY	43.63	0.98	0.43	62160
2026-03-17	SNY	44.09	0.96	0.06	61855
2026-03-18	SNY	43.72	0.94	1.87	62501
2026-03-20	SNY	44.64	0.92	2.62	62850
2026-03-25	SNY	46.06	1.12	0.06	50967
2026-03-26	SNY	46.62	1.07	0.33	52307
2026-03-27	SNY	46.8	1.03	0.69	53963
2026-03-30	SNY	46.6	1.02	0.97	54529
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	SNY	47.69	4.2	5455.8	5.01
2026-03-03	SNY	46.48	4.2	5448.5	5.01
2026-03-04	SNY	46.23	4.2	5621.1	5.01
2026-03-05	SNY	45.00	4.2	5392.8	5.01
2026-03-06	SNY	44.53	4.2	5588.7	5.01
2026-03-09	SNY	44.36	4.2	5596.8	5.01
2026-03-10	SNY	43.99	4.2	5576.4	5.01
2026-03-11	SNY	43.97	4.2	5343.3	5.01
2026-03-12	SNY	43.66	4.2	3784.6	5.01
2026-03-13	SNY	43.60	4.2	3733.7	5.01
2026-03-17	SNY	44.09	4.2	3851.1	5.01
2026-03-18	SNY	43.71	4.2	3694.4	5.01
2026-03-19	SNY	45.36	4.2	4191.6	5.01
2026-03-20	SNY	44.60	4.2	3489.5	5.01
2026-03-23	SNY	44.79	4.2	3584.3	5.01
2026-03-24	SNY	45.13	4.2	3791.6	5.01
2026-03-25	SNY	46.06	4.2	3876.2	5.01
2026-03-26	SNY	46.60	4.2	3835.5	5.01
2026-03-27	SNY	46.78	4.2	3733.3	5.01
2026-03-30	SNY	46.71	1.1	3611.9	5.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	SNY	0.00	-4.41	0.33
2026-03-03	SNY	0.00	-4.41	0.33
2026-03-04	SNY	0.00	-4.41	0.33
2026-03-05	SNY	0.00	-4.41	0.33
2026-03-06	SNY	0.00	-4.41	0.33
2026-03-09	SNY	0.00	0.46	0.33
2026-03-10	SNY	0.00	0.46	0.33
2026-03-11	SNY	0.00	0.46	0.27
2026-03-12	SNY	0.00	0.46	0.27
2026-03-13	SNY	0.00	0.46	0.27
2026-03-17	SNY	0.00	-0.31	0.27
2026-03-18	SNY	0.00	-0.31	0.27
2026-03-19	SNY	0.00	-0.31	0.27
2026-03-20	SNY	0.00	-0.31	0.27
2026-03-23	SNY	0.00	-0.08	0.27
2026-03-24	SNY	0.00	-0.08	0.27
2026-03-25	SNY	0.00	-0.08	0.31
2026-03-26	SNY	0.00	-0.08	0.31
2026-03-27	SNY	0.00	-0.08	0.31
2026-03-30	SNY	0.00	-1.87	0.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.89

Avg. EPS Est. Current Quarter

1.03

Avg. EPS Est. Next Quarter

1.11

Insider Transactions

Institutional Transactions

-1.87

Beta

0.42

Average Sales Estimate Current Quarter

10162

Average Sales Estimate Next Quarter

10804

Fair Value

59.46

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

22.3

Max Drawdown 5-Year %

-33.5

Target Price

56.4

P/E

19.57

Forward P/E

8.85

PEG

1.21

P/S

2.27

P/B

1.35

P/Free Cash Flow

10.7

EPS

2.39

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

5.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

11.81

Relative Volume

0.58

Return on Equity vs Sector %

-22

Return on Equity vs Industry %

-31.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

3611.9

◆ SNY Healthcare

$46.72

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

10/25

Volume

11/15

Valuation

18/20

TP/AR

1/10

Options

1/10

RSI

57.8

Range 1M

72.2%

Sup Dist

0.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

10/30

Estimates

5/20

Inst/Vol

0/15

Options

2/10

EPS Yr

5.8%

EPS NY

6.8%

52W%

27.6%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +36.3% upside

Quality

14/30

Valuation

15/30

Growth

8/25

Stability

4/10

LT Trend

1/5

Upside

+36.3%

Quality

MoS

27%

Sanofi

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 74846

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. Sanofi has a strategic collaboration with miRecule, Inc. to facilitate the advancement of therapy DUX4, a genetic driver of debilitating muscular disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

SNY

Latest News

—

Caricamento notizie per SNY…

stock quote shares SNY – Sanofi Stock Price stock today

news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025

marketwatch SNY – Sanofi yahoo finance google finance

stock history SNY – Sanofi invest stock market

stock prices SNY premarket after hours

ticker SNY fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.73

Margin Of Safety %

Put/Call OI Ratio

0.8

EPS Next Q Diff

4.02

EPS Last/This Y

17.69

EPS This/Next Y

0.65

Price

35.31

Target Price

47.71

Analyst Recom

2.56

Performance Q

-32.65

Upside

27.8%

Beta

0.74

Ticker: NVO

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	NVO	36.66	0.72	0.77	1568494
2026-03-04	NVO	38.45	0.72	0.50	1617740
2026-03-06	NVO	38.6	0.72	0.47	1684708
2026-03-09	NVO	39.82	0.73	0.25	1621827
2026-03-10	NVO	38.72	0.72	0.36	1637122
2026-03-11	NVO	38.85	0.72	0.46	1662327
2026-03-12	NVO	38.03	0.72	1.44	1677403
2026-03-13	NVO	38.02	0.72	1.92	1677403
2026-03-17	NVO	38.44	0.72	0.60	1666581
2026-03-18	NVO	37.47	0.72	0.63	1676885
2026-03-20	NVO	36.49	0.71	0.68	1717087
2026-03-25	NVO	36.35	0.76	1.60	1521307
2026-03-26	NVO	36.4	0.78	0.42	1548195
2026-03-27	NVO	36.07	0.77	0.59	1594485
2026-03-30	NVO	35.31	0.80	0.40	1547432
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	NVO	37.75	-24.4	-1627.7	21.05
2026-03-03	NVO	36.70	-24.4	-2372.3	21.05
2026-03-04	NVO	38.44	-24.4	-1105.7	21.05
2026-03-05	NVO	39.06	0.6	-1871.2	21.05
2026-03-06	NVO	38.58	0.6	-2339.9	21.05
2026-03-09	NVO	39.81	0.6	-1903.2	21.05
2026-03-10	NVO	38.75	0.6	-2728.2	21.05
2026-03-11	NVO	38.85	0.6	-2164.7	21.05
2026-03-12	NVO	38.03	0.6	-2729.5	21.05
2026-03-13	NVO	37.98	0.6	-2535.4	21.05
2026-03-17	NVO	38.44	0.6	-2361.5	21.05
2026-03-18	NVO	37.49	0.6	-3113.7	21.05
2026-03-19	NVO	37.07	0.6	-2780.1	21.05
2026-03-20	NVO	36.53	0.6	-2774.0	21.05
2026-03-23	NVO	36.83	0.6	-2601.1	21.05
2026-03-24	NVO	36.89	0.6	-2575.7	21.21
2026-03-25	NVO	36.34	0.6	-2696.7	21.21
2026-03-26	NVO	36.38	0.6	-2479.4	21.21
2026-03-27	NVO	36.03	0.6	-2834.9	21.21
2026-03-30	NVO	35.31	3.3	-1822.9	21.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	NVO	0.00	-0.41	0.80
2026-03-03	NVO	0.00	-0.41	0.80
2026-03-04	NVO	0.00	-0.41	0.80
2026-03-05	NVO	0.00	-0.41	0.80
2026-03-06	NVO	0.00	-0.41	0.80
2026-03-09	NVO	0.00	-0.40	0.80
2026-03-10	NVO	0.00	-0.40	0.80
2026-03-11	NVO	0.00	-0.40	0.84
2026-03-12	NVO	0.00	-0.40	0.84
2026-03-13	NVO	0.00	-0.40	0.84
2026-03-17	NVO	0.00	-0.32	0.84
2026-03-18	NVO	0.00	-0.32	0.84
2026-03-19	NVO	0.00	-0.32	0.84
2026-03-20	NVO	0.00	-0.32	0.84
2026-03-23	NVO	0.00	0.03	0.84
2026-03-24	NVO	0.00	0.03	0.84
2026-03-25	NVO	0.00	0.03	0.73
2026-03-26	NVO	0.00	0.03	0.73
2026-03-27	NVO	0.00	0.03	0.73
2026-03-30	NVO	0.00	0.30	0.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

6.74

Avg. EPS Est. Next Quarter

5.02

Insider Transactions

Institutional Transactions

0.3

Beta

0.74

Average Sales Estimate Current Quarter

74849

Average Sales Estimate Next Quarter

71393

Fair Value

44.3

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.2

Max Drawdown 5-Year %

-75.3

Target Price

47.71

P/E

10.18

Forward P/E

10.62

PEG

P/S

2.54

P/B

5.14

P/Free Cash Flow

13.28

EPS

3.47

Average EPS Est. Cur. Y

21.34

EPS Next Y. (Est.)

21.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.03

Relative Volume

0.73

Return on Equity vs Sector %

25.3

Return on Equity vs Industry %

16.1

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.29

EBIT Estimation

-1822.9

◆ NVO Healthcare

$35.29

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

7/25

Volume

9/15

Valuation

18/20

TP/AR

0/10

Options

3/10

RSI

Range 1M

1.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

8/30

Estimates

6/20

Inst/Vol

2/15

Options

7/10

EPS Yr

-11.4%

EPS NY

3.1%

52W%

0.1%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +369.5% upside

Quality

30/30

Valuation

24/30

Growth

8/25

Stability

4/10

LT Trend

4/5

Upside

+369.5%

Quality

MoS

25%

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 68794

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

OGN – Organon & Co.

OGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

7.46

Margin Of Safety %

Put/Call OI Ratio

0.82

EPS Next Q Diff

0.33

EPS Last/This Y

2.75

EPS This/Next Y

0.26

Price

5.7

Target Price

9.67

Analyst Recom

3.5

Performance Q

-20.61

Upside

177.9%

Beta

0.67

Ticker: OGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	OGN	7.2	0.80	0.62	110622
2026-03-03	OGN	6.9	0.80	0.59	110748
2026-03-04	OGN	6.86	0.80	0.66	110903
2026-03-05	OGN	6.72	0.79	1.27	110685
2026-03-06	OGN	6.56	0.79	0.42	111778
2026-03-09	OGN	6.53	0.79	1.06	112355
2026-03-10	OGN	6.47	0.78	0.67	112350
2026-03-11	OGN	6.41	0.78	0.82	112462
2026-03-12	OGN	6.33	0.77	1.05	111708
2026-03-13	OGN	6.33	0.77	1.02	111708
2026-03-17	OGN	6.39	0.75	0.47	111046
2026-03-18	OGN	6.22	0.77	0.38	112909
2026-03-19	OGN	6.26	0.76	1.65	113054
2026-03-20	OGN	6.03	0.76	0.08	113233
2026-03-23	OGN	6.09	0.89	0.11	81085
2026-03-24	OGN	6.12	0.86	0.20	82872
2026-03-25	OGN	6.1	0.84	0.25	83708
2026-03-26	OGN	6.06	0.82	0.30	84906
2026-03-27	OGN	5.84	0.81	0.74	85984
2026-03-30	OGN	5.7	0.82	2.94	86559
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	OGN	7.20	-14.7	-	3.50
2026-03-03	OGN	6.90	-15.0	-	3.50
2026-03-04	OGN	6.87	-15.0	-	3.47
2026-03-05	OGN	6.71	-15.0	-	3.47
2026-03-06	OGN	6.57	-15.0	-	3.47
2026-03-09	OGN	6.54	-15.0	-	3.47
2026-03-10	OGN	6.48	-15.0	-	3.47
2026-03-11	OGN	6.40	-15.0	-	3.47
2026-03-12	OGN	6.33	-15.0	-	3.47
2026-03-13	OGN	6.36	-15.0	-	3.47
2026-03-17	OGN	6.39	-15.0	-	3.47
2026-03-18	OGN	6.22	-15.0	-	3.47
2026-03-19	OGN	6.26	-15.0	-	3.47
2026-03-20	OGN	6.04	-15.0	-	3.47
2026-03-23	OGN	6.09	-15.0	-	3.47
2026-03-24	OGN	6.11	-15.0	-	3.47
2026-03-25	OGN	6.10	-15.0	-	3.47
2026-03-26	OGN	6.06	-15.0	-	3.47
2026-03-27	OGN	5.84	-15.0	-	3.47
2026-03-30	OGN	5.70	-15.0	-	3.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	OGN	5.78	-1.04	6.77
2026-03-03	OGN	5.78	-1.04	6.77
2026-03-04	OGN	5.78	-1.04	6.77
2026-03-05	OGN	5.77	-1.04	6.77
2026-03-06	OGN	5.78	-1.04	6.77
2026-03-09	OGN	5.78	-1.51	6.77
2026-03-10	OGN	5.78	-1.51	6.77
2026-03-11	OGN	5.79	-1.51	6.28
2026-03-12	OGN	5.78	-1.51	6.28
2026-03-13	OGN	5.78	-1.51	6.28
2026-03-17	OGN	5.78	-1.46	6.28
2026-03-18	OGN	5.78	-1.46	6.28
2026-03-19	OGN	5.77	-1.46	6.28
2026-03-20	OGN	5.78	-1.46	6.28
2026-03-23	OGN	5.78	-1.53	6.28
2026-03-24	OGN	5.78	-1.53	6.28
2026-03-25	OGN	5.78	-1.53	7.46
2026-03-26	OGN	5.78	-1.53	7.46
2026-03-27	OGN	5.78	-1.53	7.46
2026-03-30	OGN	5.78	-2.09	7.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.61

Avg. EPS Est. Current Quarter

0.87

Avg. EPS Est. Next Quarter

0.94

Insider Transactions

5.78

Institutional Transactions

-2.09

Beta

0.67

Average Sales Estimate Current Quarter

1498

Average Sales Estimate Next Quarter

1568

Fair Value

9.92

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.6

Max Drawdown 5-Year %

Target Price

9.67

P/E

7.95

Forward P/E

1.53

PEG

0.59

P/S

0.24

P/B

1.97

P/Free Cash Flow

2.76

EPS

0.72

Average EPS Est. Cur. Y

3.47

EPS Next Y. (Est.)

3.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.01

Relative Volume

0.66

Return on Equity vs Sector %

-2.6

Return on Equity vs Industry %

-11.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.4

EBIT Estimation

◆ OGN Healthcare

$5.70

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

7/25

Volume

9/15

Valuation

18/20

TP/AR

0/10

Options

4/10

RSI

23.5

Range 1M

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

1/30

Estimates

3/20

Inst/Vol

0/15

Options

2/10

EPS Yr

-5.3%

EPS NY

7.3%

52W%

0.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +705.9% upside

Quality

14/30

Valuation

27/30

Growth

2/25

Stability

4/10

LT Trend

4/5

Upside

+705.9%

Quality

MoS

74%

Organon & Co.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 10000

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

OGN

Latest News

—

Caricamento notizie per OGN…

stock quote shares OGN – Organon & Co. Stock Price stock today

news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGN – Organon & Co. yahoo finance google finance

stock history OGN – Organon & Co. invest stock market

stock prices OGN premarket after hours

ticker OGN fair value insiders trading

HZNP – Horizon Therapeutics Public Limited Company

HZNP — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

3.11

Margin Of Safety %

-6

Put/Call OI Ratio

EPS Next Q Diff

0.02

EPS Last/This Y

EPS This/Next Y

0.18

Price

116.3

Target Price

116.5

Analyst Recom

Performance Q

13.24

Upside

N/A

Beta

1.01

Ticker: HZNP

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	HZNP	116.3	N/A	N/A	0
2026-03-03	HZNP	116.3	N/A	N/A	0
2026-03-04	HZNP	116.3	N/A	N/A	0
2026-03-05	HZNP	116.3	N/A	N/A	0
2026-03-06	HZNP	116.3	N/A	N/A	0
2026-03-09	HZNP	116.3	N/A	N/A	0
2026-03-10	HZNP	116.3	N/A	N/A	0
2026-03-11	HZNP	116.3	N/A	N/A	0
2026-03-12	HZNP	116.3	N/A	N/A	0
2026-03-13	HZNP	116.3	N/A	N/A	0
2026-03-17	HZNP	116.3	N/A	N/A	0
2026-03-18	HZNP	116.3	N/A	N/A	0
2026-03-19	HZNP	116.3	N/A	N/A	0
2026-03-20	HZNP	116.3	N/A	N/A	0
2026-03-23	HZNP	116.3	N/A	N/A	0
2026-03-24	HZNP	116.3	N/A	N/A	0
2026-03-25	HZNP	116.3	N/A	N/A	0
2026-03-26	HZNP	116.3	N/A	N/A	0
2026-03-27	HZNP	116.3	N/A	N/A	0
2026-03-30	HZNP	116.3	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.22

Avg. EPS Est. Next Quarter

1.4

Insider Transactions

Institutional Transactions

1.83

Beta

1.01

Average Sales Estimate Current Quarter

954

Average Sales Estimate Next Quarter

1040

Fair Value

109.22

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

3.5

Max Drawdown 5-Year %

-50.9

Target Price

116.5

P/E

62.16

Forward P/E

18.11

PEG

12.43

P/S

7.31

P/B

5.01

P/Free Cash Flow

27.79

EPS

1.87

Average EPS Est. Cur. Y

4.64

EPS Next Y. (Est.)

5.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.02

Relative Volume

Return on Equity vs Sector %

-13.1

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1038.8

No data found for HZNP

HZNP

Latest News

—

Caricamento notizie per HZNP…

stock quote shares HZNP – Horizon Therapeutics Public Limited Company Stock Price stock today

news today HZNP – Horizon Therapeutics Public Limited Company stock forecast ,stock prediction 2023 2024 2025

marketwatch HZNP – Horizon Therapeutics Public Limited Company yahoo finance google finance

stock history HZNP – Horizon Therapeutics Public Limited Company invest stock market

stock prices HZNP premarket after hours

ticker HZNP fair value insiders trading

No more stocks to show

AMRN – Amarin Corp ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AMRN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

GRFS – Grifols, S.A.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GRFS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y